Merck, Daiichi end plans to seek speedy approval of lung cancer ADC

RegulatoryNegative

AI Analysis

Summary

Merck and Daiichi Sankyo have ended their plans to pursue accelerated approval for their lung cancer antibody-drug conjugate (ADC), representing a regulatory setback for the collaboration.

Outcome Details

Merck and Daiichi Sankyo ended plans to seek accelerated approval for a lung cancer ADC

Importance:6/10

Sentiment:

-0.60

ADClung cancerregulatory setbackpartnership

Related Companies

$MRK $DSKYF

Read the original article

Published by yahoo_finance on September 28, 2026 12:52 PM

Read Original